Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at CTAD 2025Long-term LEQEMBI treatment suggests potential to delay disease progression from MCI to moderate Alzheimer’s disease by up to 8.3 years in low-amyloid group who started treatment at an early stage

New safety and efficacy data presented at scientific symposium on subcutaneous formulation for LEQEMBI initiation treatment, which is under regulatory review in the United States